Antibacterial properties of the CFTR potentiator ivacaftor.
about
Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and DivergencesPotentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.PharmGKB summary: very important pharmacogene information for CFTRPseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.2014 year in review: Cystic fibrosis.Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis.Drug repurposing: a new front in the war against Staphylococcus aureus.Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?Drug-drug plasma protein binding interactions of ivacaftor.Pseudomonas aeruginosa Infection after CFTR Restoration. One Step Back, One Step Forward.Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor.l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites.
P2860
Q26747210-190F657D-4F0A-4801-843E-F888EAAA5642Q34748891-A5462C61-D596-45C9-B134-9183F6C0B10CQ35108743-6D283854-23C2-43BF-A917-8DB76D891C5FQ35127240-0B2FE696-5E75-4C9E-B22F-E2D15DFE576DQ35326173-E024CBF9-4604-4AA3-B349-DE550F9A3E29Q35973180-E5080BE1-2E04-4553-95C8-85C6114017B1Q37634327-5D342A88-76DF-4965-8978-84852994CE06Q38582563-6D17ABB5-F885-4A5C-BD82-2F016EF19614Q38635530-77542F3C-1FE1-41C0-AE7D-B3BA232E493CQ38834193-26B49553-5179-4637-B059-41A5F655A26DQ38835405-483FFA85-85EE-4315-9437-EFA58DDEEF45Q38996435-7677C932-5B6C-41C5-B41B-1B83D61F9290Q39036218-A5746279-4F4F-4A7F-A8D3-79450E5AC677Q40171490-EE5EE560-ADB7-4699-9C03-BD8D966B0A90Q40323696-9C0B56AD-CB54-4C89-8C11-CBC5EB55DA73Q41641680-381C322A-A6AA-43CC-B06E-57AF28111F2EQ50141673-B66C54E9-8442-49C8-9D01-70FB494E147FQ52645796-953E1FB4-7AE1-43F6-ADAA-FE3C0CF65DBE
P2860
Antibacterial properties of the CFTR potentiator ivacaftor.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Antibacterial properties of the CFTR potentiator ivacaftor.
@ast
Antibacterial properties of the CFTR potentiator ivacaftor.
@en
type
label
Antibacterial properties of the CFTR potentiator ivacaftor.
@ast
Antibacterial properties of the CFTR potentiator ivacaftor.
@en
prefLabel
Antibacterial properties of the CFTR potentiator ivacaftor.
@ast
Antibacterial properties of the CFTR potentiator ivacaftor.
@en
P2093
P2860
P50
P1476
Antibacterial properties of the CFTR potentiator ivacaftor.
@en
P2093
Cassie L Dohrn
Michael J Welsh
Nick D Gansemer
P2860
P304
P356
10.1016/J.JCF.2014.02.004
P577
2014-03-05T00:00:00Z